CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma

References

• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli J J, Sutherland J, Wilson K S, Gascoyne R D, Connors J M. Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large-B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027–5033
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Hermine O, Haioun C, Lepage E, d'Agay M F, Briere J, Lavignac C, Fillet G, Salles G, Marolleau J P, Diebold J, Reyas F, Gaulard P. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87: 265–272
   PubMed Web of Science ®Google Scholar
• Kramer M H, Hermans J, Parker J, Krol A D, Kluin-Nelemans J C, Haak H L, van Groningen K, van Krieken J H, de Jong D, Kluin P M. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996; 14: 2131–2138
   PubMed Web of Science ®Google Scholar
• Hill M E, MacLennan K A, Cunningham D C, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan-Hudson G, Mason D, Selby P, Linch D C. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study. Blood 1996; 88: 1046–1051
   PubMed Web of Science ®Google Scholar
• Gascoyne R D, Adomat S A, Krajewski S, Krajewska M, Horsman D E, Tolcher A W, O'Reilly S E, Hoskins P, Coldman A J, Reed J C, Connors J M. Prognostic significance of bcl-2 protein expression and Bcl-2 gene re-arrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244–251
   PubMed Web of Science ®Google Scholar
• Piris M A, Pezzella F, Martinez-Montero J C, Orradre J L, Villuendas R, Sanchez-Beato M, Cuena R, Cruz M A, Martinez B, Garrido M C, Gatter K, Aiello A, Delia D, Giardini R, Rilke F. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Brit J Cancer 1994; 69: 337–341
   PubMed Web of Science ®Google Scholar
• Wilson W H, Teruya-Feldstein J, Fest T, Harris C, Steinberg S M, Jaffe E S, Raffeld M. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89: 601–609
   PubMed Web of Science ®Google Scholar
• Miller T P, Levy N, Bailey N P, Kawasaki E, Baier M, Grogan T M. The bcl-2 gene translocation (T14; 18) identifies a subgroup of patients with diffuse large cell lymphoma having an indolent clinical course with late relapse. Proc Am Soc Clin Oncol 1994; 13: 370, (abstract no. 1249)
   Google Scholar
• Miyashita T, Reed J C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151–157
   PubMed Web of Science ®Google Scholar
• Simonian P L, Grillot D A, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997; 90: 1208–1216
   PubMed Web of Science ®Google Scholar
• Connors J M. BCCA Protocol summary for treatment of lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (CHOP-R) Available at http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Lymphoma/LYCHOPR.htm, accessed March 2007
   Google Scholar
• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E A, Morrison V A. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B cell lymphoma: an update. Blood 2004; 104: 40a, (abstract no. 127)
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M G, Trümper L, Ma D, Österborg A, Pettengell R, Trneny M, Shepherd L, Waleswski J, Zinzani P-L, Loeffler M. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab: Early stopping after the first interim analysis. Proc Am Soc Clin Oncol 2004; 23: 556, (abstract no. 6500)
   Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis H-E, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Hochster H S, Weller E, Gascoyne R D, Ryan T S, Habermann T M, Gordon L I, Frankel S R, Horning S J. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood (ASH Annual Meeting Abstracts) 2005; 106, (abstract no. 349)
   Google Scholar
• Salles G A, Foussard C, Nicolas M, Franck M, Chantall D, Thierry L CH, Brice P, Bouabdallah R, Rossi J, Bruno A CF, Mahe B, Feugier P, Sebban C. Rituximab added αIFN + CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood (ASH Annual Meeting Abstracts) 2004; 104, (abstract no. 160)
   Google Scholar
• Dreyling M, Forstpointner R, Ludwig W, Gramatzki M, Boeck H, Haenel M, Wandt H, Parwaresch R, Unterhalt M, Hiddemann W. Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc Am Soc Clin Oncol 2005, (abstract no. 6528)
   Google Scholar
• Van Oers M HJ, Van Glabbeke M, Teodorovic I, Rozewicz C, Klasa R, Marcus R E, Wolf M, Kimby E, Hagenbeek A. Chimeric anti-CD20 monoclonal antibody (Rituximab; Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: final analysis of a phase III randomized Intergroup clinical trial. Blood (ASH Annual Meeting Abstracts) 2005; 106: 353
   PubMed Web of Science ®Google Scholar
• Maloney D G, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29(1 Suppl 2)2–9
   PubMed Web of Science ®Google Scholar
• Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–186
   PubMed Web of Science ®Google Scholar
• Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004; 8: 1–82, iii, ix – xi
   Web of Science ®Google Scholar
• Sehn L H, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage K J, Shenkier T, Sutherland J, Gascoyne R D, Connors J M. The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, Emile J-F, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284
   PubMed Web of Science ®Google Scholar
• Wilson W H, Pittaluga S, Gutierrez M, Dunleavy K, Hegde U, Grant N, Steinberg S, Raffeld M, Grossbard M, Jaffe E, Janik J. Dose-adjusted EPOCH-rituximab in untreated diffuse large B-cell lymphoma: benefit of rituximab appears restricted to tumors harboring anti-apoptotic mechanisms. Blood 2003; 102: 105a, (abstract no. 356)
   Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Norton A, Hagenbeek A, Horning S, Lister A, Raemaekers J, Gascoyne R D, Salles G, Weller E. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25: 805–812
   PubMed Web of Science ®Google Scholar
• Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study. Ann Hematol 2004; 83: 414–419
   PubMed Web of Science ®Google Scholar
• Miller T P, Grogan T M, Dahlberg S, Spier C M, Braziel R M, Banks P M, Foucar K, Kjeldsberg C R, Levy N, Nathwani B N. Prognostic significance of the Ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphoma: a prospective South West Oncology Group Trial. Blood 1994; 83: 1460–1466
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, Gascoyne R D, Muller-Hermelink H K, Smeland E B, Giltnane J M, Hurt E M, Zhao H, Averett L, Yang L, Wilson W H, Jaffe E S, Simon R, Klausner R D, Powell J, Duffey P L, Longo D L, Greiner T C, Weisenburger D D, Sanger W G, Dave B J, Lynch J C, Vose J, Armitage J O, Montserrat E, Lopez-Guillermo A, Grogan T M, Miller T P, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt L M, Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, Muller-Hermelink H K, Campo E, Braziel R M, Jaffe E S, Pan Z, Farinha P, Smith L M, Falini B, Banham A H, Rosenwald A, Staudt L M, Connors J M, Armitage J O, Chan W C. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Lossos I S, Czerwinski D K, Alizadey A A, Wechser M A, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828–1837
   PubMed Web of Science ®Google Scholar
• Barrans S L, Carter I, Owen R G, Davies F E, Patmore R D, Haynes A P, Morgan G J, Jack A S. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143
   PubMed Web of Science ®Google Scholar
• Morel P, Mounier N, Briere J, Hermine O, Ferme C, Coiffier B, Tilly H, Gaulard P, Lederlin P, Reyes F, Gisselbrecht C. Autologous stem cell transplantation as consolidation chemotherapy for patients with low-intermediate risk diffuse large B-cell lymphoma and over-expression of BCL2 protein: results of the GELA trial LNH98-B2. Ann Oncol 2005; 16(Suppl 5)v54, (abstract no. 66)
   Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, O'Connor O, Filippa D A, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz C. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar